News about Drug Discovery & Development

Syndax Gets FDA Approval of Revuforj for Relapsed or Refractory Acute Leukemia

The safety evaluation of Revuforj was based on an FDA analysis of 135 patients with R/R acute leukemia with a KMT2A translocation who were treated with Revuforj.

Drug Discovery & Development | 16/11/2024 | By Aishwarya |  435

Endo and Paladin Pharma to Commercialize Wynzora Cream in Canada

Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults.

Drug Discovery & Development | 16/11/2024 | By Aishwarya |  517

Reverb, Royalmount Laboratories to Develop Advanced Bispecific Antibodies

Reverb’s novel Amplify•R™ platform combines bispecific antibody engineering with data-driven modelling of antibody-tissue interaction to amplify endogenous cytokines and redirect them to tissues of interest.

Drug Discovery & Development | 14/11/2024 | By Aishwarya |  420

TAE Life Sciences and Stella Pharma to Commercialize BPA for BNCT Cancer Therapy

The collaboration objectives include extensive international cooperation in the development and commercialization of BNCT and BPA across the USA and Europe with clinical trials anticipated to begin in 2026.

Drug Discovery & Development | 14/11/2024 | By Aishwarya |  692

Chime Biologics and Waterstone to Advance ADC Development and Manufacturing

Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies.

Drug Discovery & Development | 13/11/2024 | By Aishwarya |  252

Lupin Gets Tentative Approval from FDA for Raltegravir Tablets

Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients and in pediatric patients weighing at least 40 kg.

Drug Discovery & Development | 11/11/2024 | By Aishwarya |  349

Huons Acquires Stake in PanGen to Expand Bio-Pharma Business

Huons will own PanGen shares through the acquisition of existing shareholders and a paid-in capital increase via third-party allocation.

Drug Discovery & Development | 08/11/2024 | By Aishwarya |  503

Acumen Pharmaceuticals Appoints New Chief Regulatory Officer and Head of Quality

Dr. Schacterle brings over 30 years of experience in regulatory affairs, quality assurance, and therapeutic development to Acumen, with a focus on diseases of the central nervous system.

Drug Discovery & Development | 07/11/2024 | By Aishwarya |  602

Duoning Biotech and Branca Bunus to Develop Transfection Reagents

Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents, with the goal of providing biopharmaceutical customers with innovative transfection reagents through resource sharing, thereby enhancing the efficiency of biopharmaceutical development in upstream bioprocess.

Drug Discovery & Development | 07/11/2024 | By Aishwarya |  375

Syndax Signs USD 350 Million Royalty Funding Deal with Royalty Pharma for Niktimvo

Under the terms of the agreement, Syndax received an upfront payment of USD 350 million in exchange for a 13.8 percent royalty on US net sales of Niktimvo.

Drug Discovery & Development | 06/11/2024 | By Aishwarya |  653